JB Chemicals vs Indoco Remedies business model compares concentrated cardiac and gastro-intestinal therapeutic branded formulations against domestic branded formulations combined with contract manufacturing exports to see which domestic branded formulations has better business model.

Alembic vs Ipca Laboratories business model compares diversified branded generics manufacturing across multiple therapeutic categories against concentrated anti-malarial and pain management therapeutic specialisation to see which domestic branded formulations has better business model.

Glenmark Pharmaceuticals vs JB Chemicals business model compares concentrated dermatology and respiratory therapeutic focus with export presence against concentrated cardiac and gastro-intestinal therapeutic branded formulations to see which domestic branded formulations has better business model.

Ipca Laboratories vs Mankind Pharma business model compares concentrated anti-malarial and pain management therapeutic specialisation against scale-led domestic branded generics combined with consumer healthcare products to see which domestic branded formulations has better business model.

Gillette India vs Colgate Palmolive business model compares concentrated grooming and shaving products under global parent brand against concentrated oral care category leadership with toothpaste dominance to see which fmcg personal care has better business model.

Glenmark Pharmaceuticals vs Alembic business model compares concentrated dermatology and respiratory therapeutic focus with export presence against diversified branded generics manufacturing across multiple therapeutic categories to see which domestic branded formulations has better business model.

GSK Pharma vs Pfizer India business model compares concentrated vaccines and specialty pharmaceutical portfolio against innovator drug portfolio leveraging global parent research pipeline to see which mnc pharmaceuticals has better business model.

CSB Bank share price fell 2.61% to Rs 336.3 as of 23 July 2026, after the company announced its Q1 FY27 results on 22 July 2026. Q1 FY27 PAT stood at Rs 150 crore.